According to a recent analysis by Emergent Research, the worldwide interventional cardiology market is anticipated to reach USD 26.92 billion by 2027. This market is expanding as a result of the government’s increasing efforts to upgrade the healthcare system with cutting-edge diagnostic tools. To promote the use of technologically cutting-edge interventional cardiology devices, the government has boosted the financial allocation for healthcare in developing nations and created several reimbursement programs.
A significant component in the growth of the sector in emerging nations is the awareness campaigns concerning coronary heart illnesses and cutting-edge diagnostic methods that have been started by numerous non-profit organizations, academic institutions, and the government. Throughout the projected period, manufacturers will invest more money in research and development to produce technology that is more advanced, accurate, and cost-effective.
The hemodynamic flow alteration devices market has been divided into chronic complete occlusion devices and embolic protection devices based on type. In 2019, the hemodynamic flow alteration devices market was dominated by the category of embolic protection devices. This is explained by the benefits of embolic protection devices over chronic total occlusion devices, such as their capacity to collect embolic debris without halting continuous blood flow. In addition, there are more and more interventional treatments for coronary artery disorders.
Some Key Highlights From the Report:
Due to the development of technologically sophisticated stents such as bioabsorbable stents, which reduce arterial blockages, angioplasty stents dominated the market with a share of 40.3% in 2019.
Due to the advancement of the healthcare infrastructure and the employment of cutting-edge technology, the hospital segment is anticipated to dominate the end-user segment.
Due to the significant market share that North America held in 2019 for interventional cardiology and the region’s high healthcare costs, major manufacturers are investing more money in this sector.
Due to the rising urban populations in nations like China and India being impacted by the rising incidence of cardiovascular illnesses, Asia-Pacific is anticipated to see the greatest CAGR throughout the projection period.
A few notable participants are Boston Scientific Corporation, Terumo Corporation, C.R. Bard, B. Braun, Avascular, BIOTRONIK, and Biosensors, among others. Abbott Laboratories, Boston Scientific Corporation, Cordis Corporation, Medtronic Public Limited Company, and others are also significant players.
Emergen Research has segmented the global Interventional Cardiology Market based on Product, End User, and region:
Product Outlook (Revenue, USD Billion; 2017-2027)
- Catheters (Angiography Catheters, Guiding Catheters, IVUS Catheters)
- Angioplasty Balloons (Cutting Balloons, Normal Balloons, Drug-Eluting Balloons)
- Plaque Modification Devices
- Angioplasty Stents (Bioabsorbable stents, Drug-Eluting stents, Bare-Metal stents)
- Others (Guidewires, Balloon Inflation devices)
End User Outlook (Revenue, USD Billion; 2017-2027)
- Cardiac Catheterization labs
- Ambulatory surgical centers
Regional Outlook (Revenue, USD Billion; 2017-2027)
- North America
- the U.S.
- the UK
- Rest of Europe
- the Asia Pacific
- South Korea
- Rest of APAC
- Latin America
- Rest of LATAM
- Saudi Arabia
- Rest of MEA